Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4555745 | 0.90 | RXFP1 (0.51) | RXFP1HTR6KMT2APOLBGAA | |
| SCHEMBL14100642 | 0.83 | RXFP1 (0.49) | RXFP1KMT2APOLBGAAPKM | |
| SCHEMBL4554019 | 0.81 | RXFP1 (0.52) | RXFP1HTR6KMT2APOLBGAA | |
| SCHEMBL5095090 | 0.81 | HTR6 (0.55) | HTR6PKM | |
| SCHEMBL4555130 | 0.80 | RXFP1 (0.51) | RXFP1KMT2APOLBGAAPKM | |
| SCHEMBL5097223 | 0.80 | HTR6 (0.52) | HTR6 | |
| SCHEMBL5091038 | 0.76 | KHK (0.46) | RXFP1HTR6KMT2ADRD2DRD4 | |
| SCHEMBL4555077 | 0.76 | RXFP1 (0.50) | RXFP1KMT2APOLBGAAPKM | |
| SCHEMBL5213064 | 0.76 | NR3C2 (0.62) | RXFP1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL3618916 | 0.75 | POLB (0.49) | RXFP1HTR6KMT2APOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | claimed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1B, HTR1A | RXFP1 268/4885HTR6 1/4885KMT2A 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.